The biotech platform company Humacyte is merging with Alpha Healthcare Acquisition Corp. (NSDQ:AHAC) (“AHAC”), a special purpose acquisition company (SPAC).
AHAC’s shareholders approved the deal today and plan to submit results from the meeting to the SEC via a Form 8-K document.
The two organizations expect the merger to finalize on August 26 and stock shares to begin trading under the tickers “HUMA” and “HUMAW” a day later.
Based in Durham, N.C., Humacyte specializes in implantable bioengineered human tissues and organs, including acellular tissues for treating various ailments.
The company’s first product candidate, known as HAV, includes vascular cells on a polymer mesh that eventually form a cylindrical vessel structure. HAV is the first product to receive Regenerative Medicine Advanced Therapy (RMAT) designation from FDA. It has also received FDA fast track designation.
Former Duke University professor Laura Niklason and Duke University alumni Shannon Dahl and Juliana Blum founded Humacyte in 2004.
Alpha Healthcare Acquisition Corp. first reached a definitive agreement to merge with Humacyte in February 2021.
AHAC went public in late July.
Filed Under: clinical trials, Drug Discovery